Gene polymorphisms in chronic C virus hepatitis

Klára Werling, K. Rácz

Research output: Contribution to journalArticle

Abstract

The hepatitis C virus (HCV) is a major public health problem in the world. Current standard of treatment with pegylated interferonalpha (PegIFN) and ribavirin (RBV) achieves a sustained virological response in 40-50% of those infected with genotype 1. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments. The polymorphisms in IL28B are highly predictive of response to PegIFN and RBV combination therapy for HCV genotype 1 infection. Possibly combined to other baseline features, such as the measurements of IP-10 and HLA-C as well as on-treatment viral kinetics, should allow for improved prediction of response to HCV combination therapy. Host genetics have significant role in spontaneous clearance of HCV. Genotyping of this polymorphism will aid clinical decision making for both current standard of care and potentially for the integration of other agents in the future, providing an opportunity for clinicians to individualize treatment regimens for hepatitis C patients.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalInterventional Medicine and Applied Science
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Chronic Hepatitis C
Viruses
Hepacivirus
Genes
Ribavirin
Therapeutics
Genotype
HLA-C Antigens
Drug Design
Standard of Care
Hepatitis C
Public Health
Infection

Keywords

  • chronic C virus hepatitis
  • gene polymorphism
  • host genetic
  • interleukin 28B
  • therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gene polymorphisms in chronic C virus hepatitis. / Werling, Klára; Rácz, K.

In: Interventional Medicine and Applied Science, Vol. 4, No. 2, 01.06.2012, p. 69-73.

Research output: Contribution to journalArticle

@article{4136f67da7bb43e291434b2d37a4e1c8,
title = "Gene polymorphisms in chronic C virus hepatitis",
abstract = "The hepatitis C virus (HCV) is a major public health problem in the world. Current standard of treatment with pegylated interferonalpha (PegIFN) and ribavirin (RBV) achieves a sustained virological response in 40-50{\%} of those infected with genotype 1. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments. The polymorphisms in IL28B are highly predictive of response to PegIFN and RBV combination therapy for HCV genotype 1 infection. Possibly combined to other baseline features, such as the measurements of IP-10 and HLA-C as well as on-treatment viral kinetics, should allow for improved prediction of response to HCV combination therapy. Host genetics have significant role in spontaneous clearance of HCV. Genotyping of this polymorphism will aid clinical decision making for both current standard of care and potentially for the integration of other agents in the future, providing an opportunity for clinicians to individualize treatment regimens for hepatitis C patients.",
keywords = "chronic C virus hepatitis, gene polymorphism, host genetic, interleukin 28B, therapy",
author = "Kl{\'a}ra Werling and K. R{\'a}cz",
year = "2012",
month = "6",
day = "1",
doi = "10.1556/IMAS.4.2012.2.2",
language = "English",
volume = "4",
pages = "69--73",
journal = "Interventional Medicine and Applied Science",
issn = "2061-1617",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Gene polymorphisms in chronic C virus hepatitis

AU - Werling, Klára

AU - Rácz, K.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The hepatitis C virus (HCV) is a major public health problem in the world. Current standard of treatment with pegylated interferonalpha (PegIFN) and ribavirin (RBV) achieves a sustained virological response in 40-50% of those infected with genotype 1. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments. The polymorphisms in IL28B are highly predictive of response to PegIFN and RBV combination therapy for HCV genotype 1 infection. Possibly combined to other baseline features, such as the measurements of IP-10 and HLA-C as well as on-treatment viral kinetics, should allow for improved prediction of response to HCV combination therapy. Host genetics have significant role in spontaneous clearance of HCV. Genotyping of this polymorphism will aid clinical decision making for both current standard of care and potentially for the integration of other agents in the future, providing an opportunity for clinicians to individualize treatment regimens for hepatitis C patients.

AB - The hepatitis C virus (HCV) is a major public health problem in the world. Current standard of treatment with pegylated interferonalpha (PegIFN) and ribavirin (RBV) achieves a sustained virological response in 40-50% of those infected with genotype 1. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments. The polymorphisms in IL28B are highly predictive of response to PegIFN and RBV combination therapy for HCV genotype 1 infection. Possibly combined to other baseline features, such as the measurements of IP-10 and HLA-C as well as on-treatment viral kinetics, should allow for improved prediction of response to HCV combination therapy. Host genetics have significant role in spontaneous clearance of HCV. Genotyping of this polymorphism will aid clinical decision making for both current standard of care and potentially for the integration of other agents in the future, providing an opportunity for clinicians to individualize treatment regimens for hepatitis C patients.

KW - chronic C virus hepatitis

KW - gene polymorphism

KW - host genetic

KW - interleukin 28B

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84865253462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865253462&partnerID=8YFLogxK

U2 - 10.1556/IMAS.4.2012.2.2

DO - 10.1556/IMAS.4.2012.2.2

M3 - Article

VL - 4

SP - 69

EP - 73

JO - Interventional Medicine and Applied Science

JF - Interventional Medicine and Applied Science

SN - 2061-1617

IS - 2

ER -